169 related articles for article (PubMed ID: 26647886)
1. [Escape Strategies of Tumors from Immune Surveillence].
Šťastný M; Říhová B
Klin Onkol; 2015; 28 Suppl 4():4S28-37. PubMed ID: 26647886
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive cells in tumor immune escape and metastasis.
Liu Y; Cao X
J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
[TBL] [Abstract][Full Text] [Related]
3. How do tumor stem cells actively escape from host immunosurveillance?
Qi Y; Li RM; Kong FM; Li H; Yu JP; Ren XB
Biochem Biophys Res Commun; 2012 Apr; 420(4):699-703. PubMed ID: 22465008
[TBL] [Abstract][Full Text] [Related]
4. Strategies of tumor immune evasion.
Seliger B
BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
[TBL] [Abstract][Full Text] [Related]
5. [Immune system and tumors].
Terme M; Tanchot C
Ann Pathol; 2017 Feb; 37(1):11-17. PubMed ID: 28159405
[TBL] [Abstract][Full Text] [Related]
6. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
7. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
8. Natural immunity to cancer in humans.
Bindea G; Mlecnik B; Fridman WH; Pagès F; Galon J
Curr Opin Immunol; 2010 Apr; 22(2):215-22. PubMed ID: 20207124
[TBL] [Abstract][Full Text] [Related]
9. The concept of immune surveillance against tumors. The first theories.
Ribatti D
Oncotarget; 2017 Jan; 8(4):7175-7180. PubMed ID: 27764780
[TBL] [Abstract][Full Text] [Related]
10. The immune response to tumors.
Dougan M; Dranoff G
Curr Protoc Immunol; 2009 Apr; Chapter 20():20.11.1-20.11.4. PubMed ID: 19347848
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
[TBL] [Abstract][Full Text] [Related]
12. Escape from immune- and nonimmune-mediated tumor surveillance.
Malmberg KJ; Ljunggren HG
Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
[TBL] [Abstract][Full Text] [Related]
13. [Immune response and cancer].
El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
[TBL] [Abstract][Full Text] [Related]
14. Tumor escape from immune response: mechanisms and targets of activity.
Gabrilovich D; Pisarev V
Curr Drug Targets; 2003 Oct; 4(7):525-36. PubMed ID: 14535653
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunoediting from immune surveillance to immune escape.
Kim R; Emi M; Tanabe K
Immunology; 2007 May; 121(1):1-14. PubMed ID: 17386080
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape.
Salazar-Onfray F; López MN; Mendoza-Naranjo A
Cytokine Growth Factor Rev; 2007; 18(1-2):171-82. PubMed ID: 17329145
[TBL] [Abstract][Full Text] [Related]
17. [Mechanisms of tumor escape from immunologic response].
Costello RT; Gastaut JA; Olive D
Rev Med Interne; 1999 Jul; 20(7):579-88. PubMed ID: 10434348
[TBL] [Abstract][Full Text] [Related]
18. The two sides of HER2/neu: immune escape versus surveillance.
Seliger B; Kiessling R
Trends Mol Med; 2013 Nov; 19(11):677-84. PubMed ID: 24035606
[TBL] [Abstract][Full Text] [Related]
19. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
